Literature DB >> 27162689

Balanced control of both hyper and hypo-inflammatory phases as a new treatment paradigm in sepsis.

Panagiotis Tsirigotis1, Spiros Chondropoulos1, Konstantinos Gkirkas1, Josef Meletiadis1, Ioanna Dimopoulou1.   

Abstract

The immune response of the host against invading pathogens is clinically manifested as sepsis. Sepsis is a complicated process characterized by distinct phases that usually occur in a sequential manner. The initial hyper-inflammation helps in elimination of the pathogen, but potentially may lead to excessive tissue injury. Hypo-inflammation helps in restoring immune homeostasis, but may lead to significant immune suppression and death from secondary infections if not appropriately controlled. Immune-modulating intervention in sepsis should be based on a balanced control of both the hyper and the hypo-inflammatory phase.

Entities:  

Keywords:  Sepsis; cytokines; immune-suppression; inhibition; janus kinase

Year:  2016        PMID: 27162689      PMCID: PMC4842841          DOI: 10.21037/jtd.2016.03.47

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  24 in total

Review 1.  The immune response to severe bacterial infections: consequences for therapy.

Authors:  Evangelos J Giamarellos-Bourboulis; Maria Raftogiannis
Journal:  Expert Rev Anti Infect Ther       Date:  2012-03       Impact factor: 5.091

2.  Benchmarking the incidence and mortality of severe sepsis in the United States.

Authors:  David F Gaieski; J Matthew Edwards; Michael J Kallan; Brendan G Carr
Journal:  Crit Care Med       Date:  2013-05       Impact factor: 7.598

3.  Sepsis-induced apoptosis leads to active suppression of delayed-type hypersensitivity by CD8+ regulatory T cells through a TRAIL-dependent mechanism.

Authors:  Jacqueline Unsinger; Hirotaka Kazama; Jacqueline S McDonough; Thomas S Griffith; Richard S Hotchkiss; Thomas A Ferguson
Journal:  J Immunol       Date:  2010-05-12       Impact factor: 5.422

4.  Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.

Authors:  E Abraham; P F Laterre; J Garbino; S Pingleton; T Butler; T Dugernier; B Margolis; K Kudsk; W Zimmerli; P Anderson; M Reynaert; D Lew; W Lesslauer; S Passe; P Cooper; A Burdeska; M Modi; A Leighton; M Salgo; P Van der Auwera
Journal:  Crit Care Med       Date:  2001-03       Impact factor: 7.598

5.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

Authors:  S M Opal; C J Fisher; J F Dhainaut; J L Vincent; R Brase; S F Lowry; J C Sadoff; G J Slotman; H Levy; R A Balk; M P Shelly; J P Pribble; J F LaBrecque; J Lookabaugh; H Donovan; H Dubin; R Baughman; J Norman; E DeMaria; K Matzel; E Abraham; M Seneff
Journal:  Crit Care Med       Date:  1997-07       Impact factor: 7.598

Review 6.  Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach.

Authors:  Richard S Hotchkiss; Guillaume Monneret; Didier Payen
Journal:  Lancet Infect Dis       Date:  2013-03       Impact factor: 25.071

7.  Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria.

Authors:  Katherine E Kollef; Garrett E Schramm; Angela R Wills; Richard M Reichley; Scott T Micek; Marin H Kollef
Journal:  Chest       Date:  2008-08       Impact factor: 9.410

8.  Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial.

Authors:  D J Dries; G J Jurkovich; R V Maier; T P Clemmer; S N Struve; J A Weigelt; G G Stanford; D L Herr; H R Champion; F R Lewis
Journal:  Arch Surg       Date:  1994-10

9.  Treatment of Experimental Candida Sepsis with a Janus Kinase Inhibitor Controls Inflammation and Prolongs Survival.

Authors:  P Tsirigotis; N Papanikolaou; A Elefanti; P Konstantinou; K Gkirkas; D Rontogianni; N Siafakas; P Karakitsos; E Roilides; G Dimitriadis; L Zerva; J Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

10.  PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction.

Authors:  Yan Zhang; Ying Zhou; Jingsheng Lou; Jinbao Li; Lulong Bo; Keming Zhu; Xiaojian Wan; Xiaoming Deng; Zailong Cai
Journal:  Crit Care       Date:  2010-11-30       Impact factor: 9.097

View more
  7 in total

1.  Chasing the Ghost: Hyperinflammation Does Not Cause Sepsis.

Authors:  Leland Shapiro; Sias Scherger; Carlos Franco-Paredes; Amal A Gharamti; David Fraulino; Andrés F Henao-Martinez
Journal:  Front Pharmacol       Date:  2022-06-23       Impact factor: 5.988

Review 2.  Emerging therapeutic targets for sepsis.

Authors:  Elizabeth W Tindal; Brandon E Armstead; Sean F Monaghan; Daithi S Heffernan; Alfred Ayala
Journal:  Expert Opin Ther Targets       Date:  2021-04-12       Impact factor: 6.902

3.  Alpha-Chymotrypsin Protects Against Acute Lung, Kidney, and Liver Injuries and Increases Survival in CLP-Induced Sepsis in Rats Through Inhibition of TLR4/NF-κB Pathway.

Authors:  Shaymaa Ramzy Senousy; Al-Shaimaa F Ahmed; Dalia A Abdelhafeez; Mohamed Montaser A Khalifa; Mohammed A S Abourehab; Mahmoud El-Daly
Journal:  Drug Des Devel Ther       Date:  2022-09-08       Impact factor: 4.319

4.  ICOS-Fc as innovative immunomodulatory approach to counteract inflammation and organ injury in sepsis.

Authors:  Gustavo Ferreira Alves; Ian Stoppa; Eleonora Aimaretti; Chiara Monge; Raffaella Mastrocola; Elisa Porchietto; Giacomo Einaudi; Debora Collotta; Ilaria Bertocchi; Elena Boggio; Casimiro Luca Gigliotti; Nausicaa Clemente; Manuela Aragno; Daniel Fernandes; Carlo Cifani; Christoph Thiemermann; Chiara Dianzani; Umberto Dianzani; Massimo Collino
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

5.  Predicting mortality in adult patients with sepsis in the emergency department by using combinations of biomarkers and clinical scoring systems: a systematic review.

Authors:  Kirby Tong-Minh; Iris Welten; Henrik Endeman; Tjebbe Hagenaars; Christian Ramakers; Diederik Gommers; Eric van Gorp; Yuri van der Does
Journal:  BMC Emerg Med       Date:  2021-06-13

Review 6.  Sirtuins and Sepsis: Cross Talk between Redox and Epigenetic Pathways.

Authors:  Anugraha Gandhirajan; Sanjoy Roychowdhury; Vidula Vachharajani
Journal:  Antioxidants (Basel)       Date:  2021-12-21

Review 7.  Future Drug Targets in Periodontal Personalised Medicine-A Narrative Review.

Authors:  Pradeep Kumar Yadalam; V Kalaivani; Hammam Ibrahim Fageeh; Wael Ibraheem; Manea Musa Al-Ahmari; Samar Saeed Khan; Zeeshan Heera Ahmed; Hesham H Abdulkarim; Hosam Ali Baeshen; Thodur Madapusi Balaji; Shilpa Bhandi; A Thirumal Raj; Shankargouda Patil
Journal:  J Pers Med       Date:  2022-02-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.